Should schoolchildren receive pertussis vaccine?;Bør skolebarn få kikhostevaksine?

Tidsskrift for den Norske Laegeforening

Volumn 121, Issue 12, 2001, Pages 1464-1468

  Sandbu, S ^a   Nokleby H ^a   Helland, O S ^a   Feiring, B ^a   Bondevik, M ^b   Sundelin, F ^c   Storsaeter J ^d  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b Helsekontoret ^*  (Norway)

^c Grefsen Kjelsasbydelsforvaltning   (Norway)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; IMMUNOLOGY; NORWAY; PRACTICE GUIDELINE; PROSPECTIVE STUDY;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHILD; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; NORWAY; POLIOVIRUS VACCINES; PRACTICE GUIDELINES; PROSPECTIVE STUDIES;

EID: 7444236587     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Skogen V, Jenum PA, Danilova E, Koroleva VN, Halvorsen DS, Sjursen H. Immunity to diphtheria among children in Northern Norway and North-Western Russia. Vaccine 2000; 19, nr. 2-3: 197-203.
2. Blystad H, Caugant DA, Jenum P, Nøkleby H. Kikhosteutbruddet 1997-98 - Statusrapport. MSIS-rapport 1998; 26: 18.
3. The immunological basis for immunization 2. Diphteria. WHO/EPI/GEN/93.12. Genève: WHO, 1993.
4. The immunological basis for immunization 3. Tetanus. WHO/EPI/GEN/93.13. Genève: WHO, 1993.
5. The immunological basis for immunization 6. Poliomyelitis. WHO/EPI/GEN/93.16. Genève: WHO, 1993.
6. Reed GF, Meade BD, Steinhoff MC. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics 1995; 96: 600-3.
7. Ipsen J. Circulating antitoxin at the onset of diphtheria in 425 patients. J Immunol 1946; 54: 325-47.
8. Passen EL, Andersen BR. Clinical tetanus despite a «protective» level of toxin-neutralizing antibody. JAMA 1986; 255: 1171-3.
9. Dokmetjian J, Valle CD, Lavigne V, de Lujàn CM, Manghi MA. A possible explanation for the discrepancy between ELISA and neutralising antibodies to tetanus toxin. Vaccine 2000; 18: 2698-703.
10. Mark A, Carlsson R-M, Granström M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 1999; 17: 2067-72.
11. Vitek CR, Brennan MB, Gotway CA, Bragina VY, Govorukina NV, Kravtsova ON et al. Risk of diphtheria among schoolchildren in the Russian Federation in relation to time since last vaccination. Lancet 1999; 353: 355-8.
12. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 20: 1901-6.
13. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsæter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334: 349-55.
14. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996; 334: 341-8.
15. Bégué PC, Grimprel EM, Giovannangeli MD, Abitbol VI. Comparative reactogenicity and immunogenicity of booster doses of diphtheriatetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents. Pcdiatr Infect Dis J 1998; 17: 804-9.
16. Tran Minh NN, Edelman K, He Q, Viljanen MK, Arvilommi H, Mertsola J. Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children. Vaccine 1998; 16: 1604-10.
17. Davis RL, Marcuse E, Black S, Shinefield H, Givens B, Schwalbe J et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. Pediatrics 1997; 100: 767-71.